Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...
Eikon Therapeutics, a high-profile drug startup that’s raised more than $1 billion in private funding since its formation in 2019, outlined plans on Friday to go public. Run by a group of former Merck ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results